RxDoctor Payments Data

Adam Purdy, MD

Pulmonary Disease · Newport News, VANPI 1932563582

Payments from drug & device makers

$1,674in general payments, 2019–2025

Across 23 payments — averaging $72.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$948
  • Medtronic$295
  • Genentech USA, Inc.$120
  • Pulmonx Corporation$116
  • Inspire Medical Systems, Inc.$82
  • AstraZeneca$44
  • plus $68 from 3 others

What the payments were for

  • Travel & lodging$94857%
  • Food & beverage$72643%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,674 in reported general payments places this provider in the 40th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$74,094
Medicare patients
382
Services billed
995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter139$109,116
Spiriva RespimatTiotropium Bromide136$100,057
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr72$43,167
Stiolto RespimatTiotropium Br/Olodaterol Hcl44$28,040
Spiriva HandihalerTiotropium Bromide33$27,453
Incruse ElliptaUmeclidinium Bromide32$15,261
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,334
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$8,553
Advair HfaFluticasone Propion/Salmeterol17$7,933
Fluticasone-SalmeterolFluticasone Propion/Salmeterol60$7,558
Breo ElliptaFluticasone/Vilanterol15$5,703
Albuterol Sulfate HfaAlbuterol Sulfate168$4,503
Wixela InhubFluticasone Propion/Salmeterol51$3,952
Ventolin HfaAlbuterol Sulfate18$1,045
Azithromycin17$565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere$44$19,88730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →